Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial

European Urology

Volumn 70, Issue 5, 2016, Pages 760-766

  Godtman, Rebecka Arnsrud ^a   Holmberg, Erik ^b   Khatami, Ali ^a   Pihl, Carl Gustaf ^b   Stranne, Johan ^a   Hugosson, Jonas ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Active surveillance; Outcome; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SURVEILLANCE; FAILURE FREE SURVIVAL; FOLLOW UP; HUMAN; INTERMEDIATE RISK PATIENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADVERSE DRUG REACTION; BIOPSY; DISEASE FREE SURVIVAL; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSTATE; PROSTATE TUMOR; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SWEDEN;

AGED; BIOPSY; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; HUMANS; KAPLAN-MEIER ESTIMATE; LONG TERM ADVERSE EFFECTS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SWEDEN;

EID: 84963668076     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.03.048     Document Type: Article

References (28)

1. [1] Cooperberg, M.R., Carroll, P.R., Trends in management for patients with localized prostate cancer, 1990-2013. JAMA 314 (2015), 80–82.
2. [2] Loeb, S., Berglund, A., Stattin, P., Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol 190 (2013), 1742–1749.
3. [3] The National Board of Health and Welfare, Sweden. Nationella riktlinjer för bröst-, prostata-, tjocktarms- och ändtarmscancervård 2014. http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19383/2014-4-2.pdf.
4. [4] Mottet N, Bellmunt J, Briers E, et al. EAU Guidelines on prostate cancer. http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf.
5. [5] Mohler, J.L., Kantoff, P.W., Armstrong, A.J., et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw 12 (2014), 686–718.
6. [6] Klotz, L., Vesprini, D., Sethukavalan, P., et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33 (2015), 272–277.
7. [7] Bul, M., Zhu, X., Valdagni, R., et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63 (2013), 597–603.
8. [8] Soloway, M.S., Soloway, C.T., Eldefrawy, A., Acosta, K., Kava, B., Manoharan, M., Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 58 (2010), 831–835.
9. [9] Barayan, G.A., Brimo, F., Begin, L.R., et al. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort. BJU Int 114 (2014), E99–E104.
10. [10] Selvadurai, E.D., Singhera, M., Thomas, K., et al. Medium-term outcomes of active surveillance for localized prostate cancer. Eur Urol 64 (2013), 981–987.
11. [11] Stattin, P., Holmberg, E., Johansson, J.E., Holmberg, L., Adolfsson, J., Hugosson, J., Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 102 (2010), 950–958.
12. [12] Welty, C.J., Cowan, J.E., Nguyen, H., et al. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol 193 (2015), 807–811.
13. [13] Tosoian, J.J., Mamawala, M., Epstein, J.I., et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 33 (2015), 3379–3385.
14. [14] Bul, M., van den Bergh, R.C., Zhu, X., et al. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110 (2012), 1672–1677.
15. [15] Godtman, R.A., Holmberg, E., Khatami, A., Stranne, J., Hugosson, J., Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial. Eur Urol 63 (2013), 101–107.
16. [16] Hugosson, J., Carlsson, S., Aus, G., et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11 (2010), 725–732.
17. [17] Epstein, J.I., Allsbrook, W.C. Jr., Amin, M.B., Egevad, L.L., The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29 (2005), 1228–1242.
18. [18] Fine, J.P., Gray, R.J., A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999), 496–509.
19. [19] van den Bergh, R.C., Albertsen, P.C., Bangma, C.H., et al. Timing of curative treatment for prostate cancer: A systematic review. Eur Urol 64 (2013), 204–215.
20. [20] Popiolek, M., Rider, J.R., Andren, O., et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol 63 (2013), 428–435.
21. [21] Draisma, G., Boer, R., Otto, S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003), 868–878.
22. [22] Eggener, S.E., Badani, K., Barocas, D.A., et al. Gleason 6 prostate cancer: Translating biology into population health. J Urol 194 (2015), 626–634.
23. [23] Eggener, S.E., Scardino, P.T., Walsh, P.C., et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185 (2011), 869–875.
24. [24] Wilt, T.J., Brawer, M.K., Jones, K.M., et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367 (2012), 203–213.
25. [25] Bill-Axelson, A., Holmberg, L., Garmo, H., et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370 (2014), 932–942.
26. [26] Bjurlin, M.A., Taneja, S.S., Standards for prostate biopsy. Curr Opin Urol 24 (2014), 155–161.
27. [27] Klotz, L., Defining progression” and triggers for curative intervention during active surveillance. Curr Opin Urol 25 (2015), 258–266.
28. [28] Bokhorst, L.P., Alberts, A.R., Rannikko, A., et al. Compliance rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers. Eur Urol 68 (2015), 814–821.